INTERPACE BIOSCIENCES, INC. (IDXG) Form 8-K — May 14, 2026
Interpace Biosciences reported Q1 2026 revenue of $9.0 million, representing a 12% year-over-year increase in thyroid-specific revenue and a 14% increase on a pro-forma basis after excluding the discontinued PancraGEN business. The company delivered $0.8 million in income from continuing operations and $1.6 million in Adjusted EBITDA, with gross margin expanding to 65% and operating margin improving to 12% on a pro-forma basis, reflecting operational efficiency gains.
Key figures
- Eps
- 0.03
- Revenue
- 9032000
- Guidance
- Approximately 16% year-over-year thyroid revenue growth for 2026
- Net Income
- 721000
- Total Debt
- 0
- Revenue Yoy
- -22%
- Total Assets
- 33409000
- Cash Position
- 2647000
- Gross Margin
- 65%
- Adjusted EBITDA
- 1560000
- Cash Collections
- 8700000
- Operating Income
- 1123000
- Operating Margin
- 12%
- Pro Forma Gross Margin
- 65%
- Adjusted EBITDAMargin
- 17%
- Pro Forma Adjusted EBITDA
- 1560000
- Pro Forma Operating Margin
- 12%
- Thyroid Revenue Growth Yo Y
- 12%
- Pro Forma Revenue Growth Yo Y
- 14%
Price after filing
Close on the filing date to close N calendar days later (from $1.80). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.